Model Medicines is proud to announce that our Co-Founder and CEO, Dr. Daniel Haders II, will participate in Bloomberg Intelligence's 4th Annual Generative AI Conference, titled "Generative AI: Scaling Laws Post DeepSeek," on April 2, 2025, in New York City. The event gathers industry leaders, tech innovators, and experts to discuss the latest advancements in generative AI technologies, including scaling laws for large language models (LLMs), synthetic data generation, and transformative use cases.

Dr. Haders will join a distinguished panel on "Gen AI and Drug Discovery," alongside Sean McClain, Founder and CEO of Absci, with moderation by Andrew Galler, Senior Analyst for Biotechnology at Bloomberg Intelligence. This session will focus on the impact of generative AI in identifying novel therapeutic targets and accelerating the development of innovative pharmaceuticals. Dr. Haders will share insights from Model Medicines' groundbreaking use of the GALILEO™ AI platform, which has successfully advanced numerous first-in-class drug candidates.

The conference features an impressive lineup of speakers, including executives from AWS, Anthropic, Google Cloud, Cerebras, Microsoft, and more, providing a comprehensive exploration of generative AI's future trajectory and practical applications across various industries.